Уважаемая Мина!
Не рекомендуется, что бы запасы железа в печени были высокие, те ферритин крови был свыше 50-60 мкг/л. Я же веду речь о тканевом содержании железа, когда ферритин менее 15-20 мкг и соотношение Fе/ОЖСС менее 15-20%.
О какой дозе и продолжительности идет речь относительно эритромицина?, маловероятно, что после азитромицина эритромицин может помочь.
Может имеет смысл попринимать клюквенный экстракт/сок? Согласно недавним американским рекомендациям:
Curr Urol Rep. 2003 Oct;4(5):399-403.
Recurrent urinary tract infection in women: emerging concepts regarding etiology and treatment considerations.
Gormley EA.
Dartmouth-Hitchcock Medical Center, Section of Urology, One Medical Center Drive, Lebanon, NH 03756, USA.
Recurrent urinary tract infections are caused by a combination of host factors and bacterial virulence. The patient with symptoms suggestive of recurrent urinary tract infections benefits from cultures to confirm the diagnosis of recurrent infections. The community also benefits because they allow for the tracking of resistant patterns. Once a patient has been diagnosed with recurrent urinary tract infections, there are a number of treatment choices in terms of initial treatment and prophylaxis. Treatment of the acute infection should follow the published guidelines of the Infectious Diseases Society of America taking into account local patterns of resistance. Younger patients can prevent infections by avoiding spermicides and taking cranberry tablets. Older patients may prevent infections by using estrogen and emptying their bladders fully. All patients may benefit from using antibiotic prophylaxis.
Infect Dis Clin North Am. 2003 Jun;17(2):457-71.
Novel approaches to prevention of urinary tract infections.
Stapleton A.
Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, 1959 NE Pacific Avenue, Box 356523, Seattle, WA 98195, USA.
stapl@u.washington.edu
Urinary tract infections are common clinical entities occurring in a variety of patient groups, most frequently caused by uropathogenic E. coli. Novel methods of preventing UTI currently under development are focused on three key approaches: (1) use of cranberry products, (2) restoration of the normal flora using Lactobacillus-based probiotic preparations, and (3) vaccine development. Although promising studies in each of these areas have been published or are ongoing, additional properly designed and powered clinical studies based on solid scientific evidence are needed.